Compare · INSM vs MRK
INSM vs MRK
Side-by-side comparison of Insmed Incorporated (INSM) and Merck & Company Inc. (MRK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INSM and MRK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- MRK is the larger of the two at $298.33B, about 14.6x INSM ($20.42B).
- Over the past year, INSM is up 33.2% and MRK is up 52.5% - MRK leads by 19.2 points.
- MRK has been more active in the news (26 items in the past 4 weeks vs 9 for INSM).
- Both have 25 recent analyst ratings on file.
- Company
- Insmed Incorporated
- Merck & Company Inc.
- Price
- $94.15-10.25%
- $120.88+0.51%
- Market cap
- $20.42B
- $298.33B
- 1M return
- -31.24%
- +6.46%
- 1Y return
- +33.21%
- +52.45%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 9
- 26
- Recent ratings
- 25
- 25
Insmed Incorporated
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Merck & Company Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; and Linnaeus Therapeutics, Inc. to evaluate LNS8801 in combination with KEYTRUDA for patients with advanced cancer. It also has a collaboration with Biomed X Gmbh for building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases); and a collaboration agreement with NGM Biopharmaceuticals, Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Latest INSM
- Chief Operating Officer Adsett Roger sold $242,380 worth of shares (2,370 units at $102.27), decreasing direct ownership by 2% to 98,603 units (SEC Form 4) (tax liability)
- Chief Financial Officer Bonstein Sara sold $245,857 worth of shares (2,404 units at $102.27), decreasing direct ownership by 3% to 69,082 units (SEC Form 4) (tax withholding)
- Chief Legal Officer Smith Michael Alexander sold $220,801 worth of shares (2,159 units at $102.27), decreasing direct ownership by 5% to 39,454 units (SEC Form 4) (tax liability)
- Chief Medical Officer Flammer Martina M.D. sold $455,248 worth of shares (4,424 units at $102.90) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 60,486 units (SEC Form 4) to satisfy withholding obligation
- Chair and CEO Lewis William sold $777,763 worth of shares (7,605 units at $102.27), decreasing direct ownership by 3% to 265,432 units (SEC Form 4) (for tax liability)
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
- Chief Legal Officer Smith Michael Alexander sold $666,982 worth of shares (6,149 units at $108.47) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 41,613 units (SEC Form 4)
- Chair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $2,718,224 worth of shares (25,564 units at $106.33) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 273,037 units (SEC Form 4)
- SEC Form S-3ASR filed by Insmed Incorporated
Latest MRK
- Apotex launches sitagliptin tablets and sitagliptin and metformin hydrochloride tablets, eligible for 180-day shared exclusivity
- SEC Form 4 filed by Director Warden Kathy J
- SEC Form 4 filed by Director Karsanbhai Surendralal Lanca
- SEC Form 4 filed by Director Coe Mary Ellen
- SEC Form 4 filed by Director Thulin Inge G
- SEC Form 4 filed by Director Seidman Christine E
- SEC Form 4 filed by Director Russo Patricia F
- SEC Form 4 filed by Director Rothman Paul
- SEC Form 4 filed by Director Mayo Stephen
- SEC Form 4 filed by Director Lavizzo-Mourey Risa J